{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:37:34Z","timestamp":1790120254318,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To evaluate the changes in disease-related biomarkers and safety of paquinimod, an oral immunomodulatory compound, in patients with systemic sclerosis (SSc).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this open-label, single-arm, multicenter study, SSc patients with a rapidly progressive disease received paquinimod for 8\u2009weeks. Blood and skin biopsies were collected at baseline, during treatment, and at follow-up for the analyses of type I interferon (IFN) activity, chemokine (C-C motif) ligand 2 (CCL2), and the number of myofibroblasts. The safety of paquinimod was evaluated throughout the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nine SSc patients were enrolled and completed the study treatment with paquinimod at 3\u2009mg\/day for 8\u2009weeks. After the treatment, a reduction of type I IFN activity in the plasma from one patient with elevated baseline IFN activity was recorded. A trend towards reduced IFN activity in the skin after treatment was also observed in patients. The serum level of CCL2 was reduced in 7 of 9 patients after paquinimod treatment. There was a median reduction of 10% of the number of myofibroblasts in skin biopsies at week 8 compared to baseline. No change in modified Rodnan skin score and quality of life was detected in the study. Reported adverse events (AEs) were mild to moderate and expected with the most common being arthralgia (<jats:italic>n<\/jats:italic> = 3) and headache (<jats:italic>n<\/jats:italic> = 3), and C-reactive protein (CRP) increase.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Analysis of biomarkers before and after treatment suggest reduced type I IFN activity and reduced number of myofibroblasts in lesional skin. Paquinimod was overall well tolerated with mild to moderate and expected AEs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01487551?term=paquinimod&amp;draw=2&amp;rank=2\">NCT01487551<\/jats:ext-link>. Registered on 7 September 2011<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02573-0","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T04:15:09Z","timestamp":1627704909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod"],"prefix":"10.1186","volume":"23","author":[{"given":"Roger","family":"Hesselstrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg H. W.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk M.","family":"Wuttge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"T\u00f6rngren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hel\u00e9n C.","family":"Nyhl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9899-7600","authenticated-orcid":false,"given":"Helena","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Sparre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hel\u00e9n","family":"Tuvesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,31]]},"reference":[{"issue":"3","key":"2573_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5301\/jsrd.5000249","volume":"2","author":"J Varga","year":"2017","unstructured":"Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Rel Disord. 2017;2(3):137\u201352.","journal-title":"J Scleroderma Rel Disord"},{"issue":"11","key":"2573_CR2","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1136\/ard.57.11.682","volume":"57","author":"R Hesselstrand","year":"1998","unstructured":"Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis. 1998;57(11):682\u20136. https:\/\/doi.org\/10.1136\/ard.57.11.682.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2573_CR3","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3899\/jrheum.121390","volume":"40","author":"AM Hoffmann-Vold","year":"2013","unstructured":"Hoffmann-Vold AM, Molberg O, Midtvedt O, Garen T, Gran JT. Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis. J Rheumatol. 2013;40(7):1127\u201333. https:\/\/doi.org\/10.3899\/jrheum.121390.","journal-title":"J Rheumatol"},{"issue":"1","key":"2573_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/rheumatology\/37.1.39","volume":"37","author":"S Jacobsen","year":"1998","unstructured":"Jacobsen S, Halberg P, Ullman S, Van Venrooij WJ, Hoier-Madsen M, Wiik A, et al. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol. 1998;37(1):39\u201345. https:\/\/doi.org\/10.1093\/rheumatology\/37.1.39.","journal-title":"Br J Rheumatol"},{"issue":"8","key":"2573_CR5","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327\u201339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2573_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","volume":"15","author":"JHW Distler","year":"2019","unstructured":"Distler JHW, Gyorfi AH, Ramanujam M, Whitfield ML, Konigshoff M, Lafyatis R. Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol. 2019;15(12):705\u201330. https:\/\/doi.org\/10.1038\/s41584-019-0322-7.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"2573_CR7","first-page":"1202","volume":"19","author":"O Ishikawa","year":"1992","unstructured":"Ishikawa O, Ishikawa H. Macrophage infiltration in the skin of patients with systemic sclerosis. J Rheumatol. 1992;19(8):1202\u20136.","journal-title":"J Rheumatol"},{"issue":"5","key":"2573_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41584-019-0212-z","volume":"15","author":"G Kania","year":"2019","unstructured":"Kania G, Rudnik M, Distler O. Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis. Nat Rev Rheumatol. 2019;15(5):288\u2013302. https:\/\/doi.org\/10.1038\/s41584-019-0212-z.","journal-title":"Nat Rev Rheumatol"},{"issue":"24","key":"2573_CR9","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. Jama. 2014;311(24):2490\u20138. https:\/\/doi.org\/10.1001\/jama.2014.6368.","journal-title":"Jama"},{"issue":"5","key":"2573_CR10","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1042\/CS20130367","volume":"126","author":"S O\u2019Reilly","year":"2014","unstructured":"O\u2019Reilly S. Innate immunity in systemic sclerosis pathogenesis. Clin Sci. 2014;126(5):329\u201337. https:\/\/doi.org\/10.1042\/CS20130367.","journal-title":"Clin Sci"},{"key":"2573_CR11","doi-asserted-by":"publisher","first-page":"154635","DOI":"10.1016\/j.cyto.2018.12.018","volume":"132","author":"B Skaug","year":"2020","unstructured":"Skaug B, Assassi S. Type I interferon dysregulation in systemic sclerosis. Cytokine. 2020;132:154635. https:\/\/doi.org\/10.1016\/j.cyto.2018.12.018.","journal-title":"Cytokine"},{"issue":"8","key":"2573_CR12","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","volume":"75","author":"Z Brkic","year":"2016","unstructured":"Brkic Z, van Bon L, Cossu M, van Helden-Meeuwsen CG, Vonk MC, Knaapen H, et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis. 2016;75(8):1567\u201373. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207392.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2573_CR13","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1136\/ard.2011.150326","volume":"70","author":"BW Higgs","year":"2011","unstructured":"Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis. 2011;70(11):2029\u201336. https:\/\/doi.org\/10.1136\/ard.2011.150326.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2573_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/03009742.2012.736532","volume":"42","author":"DM Wuttge","year":"2013","unstructured":"Wuttge DM, Lood C, Tufvesson E, Scheja A, Truedsson L, Bengtsson AA, et al. Increased serum type I interferon activity in early systemic sclerosis patients is associated with antibodies against Sjogren\u2019s syndrome antigens and nuclear ribonucleoprotein antigens. Scand J Rheumatol. 2013;42(3):235\u201340. https:\/\/doi.org\/10.3109\/03009742.2012.736532.","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"2573_CR15","doi-asserted-by":"publisher","first-page":"R128","DOI":"10.1186\/ar3066","volume":"12","author":"N Higashi-Kuwata","year":"2010","unstructured":"Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et al. Characterization of monocyte\/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther. 2010;12(4):R128. https:\/\/doi.org\/10.1186\/ar3066.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"2573_CR16","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1021\/jm031044w","volume":"47","author":"S Jonsson","year":"2004","unstructured":"Jonsson S, Andersson G, Fex T, Fristedt T, Hedlund G, Jansson K, et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem. 2004;47(8):2075\u201388. https:\/\/doi.org\/10.1021\/jm031044w.","journal-title":"J Med Chem"},{"issue":"4","key":"2573_CR17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00415-014-7264-4","volume":"261","author":"TL Vollmer","year":"2014","unstructured":"Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol. 2014;261(4):773\u201383. https:\/\/doi.org\/10.1007\/s00415-014-7264-4.","journal-title":"J Neurol"},{"issue":"11","key":"2573_CR18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1056\/NEJMoa1104318","volume":"366","author":"G Comi","year":"2012","unstructured":"Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366(11):1000\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1104318.","journal-title":"N Engl J Med"},{"issue":"4","key":"2573_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000097","volume":"7","author":"P Bjork","year":"2009","unstructured":"Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009;7(4):e97. https:\/\/doi.org\/10.1371\/journal.pbio.1000097.","journal-title":"PLoS Biol"},{"issue":"12","key":"2573_CR20","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1002\/art.20631","volume":"50","author":"D Foell","year":"2004","unstructured":"Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum. 2004;50(12):3762\u201371. https:\/\/doi.org\/10.1002\/art.20631.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2573_CR21","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1038\/jid.2014.253","volume":"134","author":"J Nikitorowicz-Buniak","year":"2014","unstructured":"Nikitorowicz-Buniak J, Shiwen X, Denton CP, Abraham D, Stratton R. Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9. J Investigative Dermatol. 2014;134(11):2693\u2013702. https:\/\/doi.org\/10.1038\/jid.2014.253.","journal-title":"J Investigative Dermatol"},{"issue":"10","key":"2573_CR22","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s10067-013-2305-4","volume":"32","author":"X Xu","year":"2013","unstructured":"Xu X, Wu WY, Tu WZ, Chu HY, Zhu XX, Liang MR, et al. Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities. Clin Rheumatol. 2013;32(10):1501\u201310. https:\/\/doi.org\/10.1007\/s10067-013-2305-4.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"2573_CR23","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.ajpath.2013.01.032","volume":"182","author":"S Helmersson","year":"2013","unstructured":"Helmersson S, Sundstedt A, Deronic A, Leanderson T, Ivars F. Amelioration of experimental autoimmune encephalomyelitis by the quinoline-3-carboxamide paquinimod: reduced priming of proinflammatory effector CD4(+) T cells. Am J Pathol. 2013;182(5):1671\u201380. https:\/\/doi.org\/10.1016\/j.ajpath.2013.01.032.","journal-title":"Am J Pathol"},{"issue":"5","key":"2573_CR24","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/art.33493","volume":"64","author":"AA Bengtsson","year":"2012","unstructured":"Bengtsson AA, Sturfelt G, Lood C, Ronnblom L, van Vollenhoven RF, Axelsson B, et al. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(5):1579\u201388. https:\/\/doi.org\/10.1002\/art.33493.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2573_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.atherosclerosis.2013.02.023","volume":"228","author":"L Yan","year":"2013","unstructured":"Yan L, Bjork P, Butuc R, Gawdzik J, Earley J, Kim G, et al. Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice. Atherosclerosis. 2013;228(1):69\u201379. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.02.023.","journal-title":"Atherosclerosis"},{"issue":"9","key":"2573_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203228","volume":"13","author":"N Fransen Pettersson","year":"2018","unstructured":"Fransen Pettersson N, Deronic A, Nilsson J, Hannibal TD, Hansen L, Schmidt-Christensen A, et al. The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis. PLoS One. 2018;13(9):e0203228. https:\/\/doi.org\/10.1371\/journal.pone.0203228.","journal-title":"PLoS One"},{"issue":"1","key":"2573_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jdermsci.2016.04.006","volume":"83","author":"M Stenstrom","year":"2016","unstructured":"Stenstrom M, Nyhlen HC, Torngren M, Liberg D, Sparre B, Tuvesson H, et al. Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis. J Dermatol Sci. 2016;83(1):52\u20139. https:\/\/doi.org\/10.1016\/j.jdermsci.2016.04.006.","journal-title":"J Dermatol Sci"},{"key":"2573_CR28","volume-title":"Poster presented at Eular Annual European Congress of Rheumatology","author":"ASG Bengtsson","year":"2011","unstructured":"Bengtsson ASG, R\u00f6nnblom L, Gunnarsson I, Svenungsson E, Jacobsen S, Lood C, et al. An exploratory study to evaluate changes in disease activity and biomarkers during treatment with ABR-215757 in patients with mild active systemic lupus erythematosus (SLE). In: Poster presented at Eular Annual European Congress of Rheumatology; 2011."},{"issue":"5","key":"2573_CR29","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"A Masi","year":"1980","unstructured":"Masi A, RG, Medsger T. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581\u201390. https:\/\/doi.org\/10.1002\/art.1780230510.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2573_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/ard.2009.127621","volume":"70","author":"RT Domsic","year":"2011","unstructured":"Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis. 2011;70(1):104\u20139. https:\/\/doi.org\/10.1136\/ard.2009.127621.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2573_CR31","first-page":"1281","volume":"22","author":"P Clements","year":"1995","unstructured":"Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22(7):1281\u20135.","journal-title":"J Rheumatol"},{"key":"2573_CR32","unstructured":"Bengtsson A SG, R\u00f6nnblom L, van Vollenhoven R, Wall\u00e9n \u00d6hman M, Tuvesson H, Lando P, Edman K, Liberg D, K\u00e4llberg E, Olsson A, Leanderson T: A phase I, dose escalation study to evaluate the tolerability of ABR-215757 in patients with systemic lupus erythematosus (SLE). Poster presented at EULAR (The European League Against Rheumatism) Conference, Copenhagen, Denmark 2009, June 10 (Active Biotech Doc. No. 0930104)."},{"issue":"1","key":"2573_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/0014-4827(61)90059-3","volume":"23","author":"L Hayflick","year":"1961","unstructured":"Hayflick L. The establishment of a line (WISH) of human amnion cells in continuous cultivation. Exp Cell Res. 1961;23(1):14\u201320. https:\/\/doi.org\/10.1016\/0014-4827(61)90059-3.","journal-title":"Exp Cell Res"},{"key":"2573_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3389\/fimmu.2013.00266","volume":"4","author":"M Wu","year":"2013","unstructured":"Wu M, Assassi S. The role of type 1 interferon in systemic sclerosis. Front Immunol. 2013;4:266.","journal-title":"Front Immunol"},{"issue":"1","key":"2573_CR35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/art.21497","volume":"54","author":"JH Distler","year":"2006","unstructured":"Distler JH, Jungel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum. 2006;54(1):214\u201325. https:\/\/doi.org\/10.1002\/art.21497.","journal-title":"Arthritis Rheum"},{"key":"2573_CR36","doi-asserted-by":"publisher","unstructured":"Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum. 2001;44(11):2665\u201378. https:\/\/doi.org\/10.1002\/1529-0131(200111)44:11<2665::AID-ART446>3.0.CO;2-S.","DOI":"10.1002\/1529-0131(200111)44:11<2665::AID-ART446>3.0.CO;2-S"},{"issue":"12","key":"2573_CR37","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1002\/art.21396","volume":"52","author":"MT Carulli","year":"2005","unstructured":"Carulli MT, Ong VH, Ponticos M, Shiwen X, Abraham DJ, Black CM, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum. 2005;52(12):3772\u201382. https:\/\/doi.org\/10.1002\/art.21396.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2573_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.intimp.2013.12.008","volume":"18","author":"A Deronic","year":"2014","unstructured":"Deronic A, Helmersson S, Leanderson T, Ivars F. The quinoline-3-carboxamide paquinimod (ABR-215757) reduces leukocyte recruitment during sterile inflammation: leukocyte- and context-specific effects. Int Immunopharmacol. 2014;18(2):290\u20137. https:\/\/doi.org\/10.1016\/j.intimp.2013.12.008.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"2573_CR39","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/art.27220","volume":"62","author":"G Farina","year":"2010","unstructured":"Farina G, Lafyatis D, Lemaire R, Lafyatis R. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2010;62(2):580\u20138. https:\/\/doi.org\/10.1002\/art.27220.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2573_CR40","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/art.27224","volume":"62","author":"S Assassi","year":"2010","unstructured":"Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum. 2010;62(2):589\u201398. https:\/\/doi.org\/10.1002\/art.27224.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2573_CR41","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1186\/ar4492","volume":"16","author":"A Goldberg","year":"2014","unstructured":"Goldberg A, Geppert T, Schiopu E, Frech T, Hsu V, Simms RW, et al. Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014;16(1):R57. https:\/\/doi.org\/10.1186\/ar4492.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"2573_CR42","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1002\/art.22186","volume":"54","author":"EY Kissin","year":"2006","unstructured":"Kissin EY, Merkel PA, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum. 2006;54(11):3655\u201360. https:\/\/doi.org\/10.1002\/art.22186.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2573_CR43","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/art.24249","volume":"60","author":"R Lafyatis","year":"2009","unstructured":"Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60(2):578\u201383. https:\/\/doi.org\/10.1002\/art.24249.","journal-title":"Arthritis Rheum"},{"key":"2573_CR44","doi-asserted-by":"publisher","first-page":"622326","DOI":"10.3389\/fimmu.2020.622326","volume":"11","author":"H Enocsson","year":"2020","unstructured":"Enocsson H, Gullstrand B, Eloranta ML, Wettero J, Leonard D, Ronnblom L, et al. C-reactive protein levels in systemic lupus erythematosus are modulated by the interferon gene signature and CRP gene polymorphism rs1205. Front Immunol. 2020;11:622326.","journal-title":"Front Immunol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02573-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02573-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02573-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T04:17:08Z","timestamp":1627705028000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02573-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,31]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2573"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02573-0","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,31]]},"assertion":[{"value":"12 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in Sweden, Germany, and Switzerland, and the protocol was approved by the national authorities and local ethical committees (Kantonale Ethik Kommission, KEK, Zurich; Ethik-Kommission, Erlangen; Regionala etikpr\u00f6vningsn\u00e4mnden, EPN, Lund) performed in accordance with the Declaration of Helsinki. All patients provided written informed consent. Ethical approval for animal studies is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RH received funding from Active Biotech AB related to the study. JHWD has consultancy relationships with Actelion, Active Biotech, Anamar, ARXX, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JB Therapeutics, Medac, Pfizer, RuiYi, and UCB. JHWD has received research funding from Anamar, Active Biotech, Array Biopharma, ARXX, aTyr, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, Novartis, Sanofi-Aventis, RedX, and UCB. JHWD is a stock owner of 4D Science.GR and DMW declare that they have no competing interests.MT, HT, and HE are employees and stock owners of Active Biotech AB.HCN is a former employee at Active Biotech AB and owns stocks in Active Biotech AB.FA and BS are former employees at Active Biotech AB.OD has\/had consultancy relationship and\/or has received research funding from Abbvie, Actelion, Acceleron Pharma, Amgen, AnaMar, Baecon Discovery, Blade Therapeutics, Bayer, Boehringer Ingelheim, Catenion, Competitive Drug Development International Ltd., CSL Behring, ChemomAb, Curzion Pharmaceuticals, Ergonex, Galapagos NV, Glenmark Pharmaceuticals, GSK, Inventiva, Italfarmaco, iQone, iQvia, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Sanofi, Target BioScience, and UCB in the area of potential treatments of scleroderma and its complications. He has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"204"}}